GEMMABio Welcomes Dr. May Orfali as Chief Medical Officer
GEMMA Biotherapeutics, known as GEMMABio, has made an exciting announcement regarding its leadership team. The company has appointed Dr. May Orfali as its new Chief Medical Officer, bringing with her an impressive background in clinical development and medical affairs.
Dr. May Orfali's Extensive Background
Dr. Orfali comes with nearly 30 years of experience in the medical field, showcasing an expansive knowledge base across various therapeutic areas. Her expertise includes oncology, infectious diseases, and the challenges associated with rare and orphan diseases. Throughout her career, she has successfully led clinical development initiatives, managed clinical operations, and directed various aspects of medical affairs and regulatory strategies for numerous successful pharmaceutical companies.
A Warm Welcome
Expressing the company's excitement, Dr. Jim Wilson, the President and CEO of GEMMABio, stated, "We are thrilled to welcome May to our team, whose multi-faceted background in pharmaceuticals and international health coupled with her proven leadership in advancing clinical programs will be hugely impactful to our growing company." With her experience overseeing innovative programs involving data analytics, artificial intelligence, and biological biomarkers, Dr. Orfali is well-equipped to lead GEMMABio's clinical operations.
Previous Roles and Expertise
Before joining GEMMABio, Dr. Orfali served as the Chief Medical Officer at Harbinger Health, focusing on developing multicancer early detection products that leverage AI technology. In this role, she was instrumental in shaping clinical development, operations, and medical strategy. She also held the position of Executive Vice President and Chief Medical Officer at Sigilon Therapeutics, which was acquired by Eli Lilly in 2023.
Inspiring Mission
Throughout her impressive career, Dr. Orfali has contributed to many reputable organizations such as Pfizer, Boston Scientific Corporation, the World Health Organization, and UNICEF. She noted, "I am deeply inspired by GEMMABio's mission to advance innovative gene therapy research and deliver effective therapeutics globally, which will revolutionize the field of genetic medicines." Dr. Orfali is eager to collaborate with the talented team to improve the lives of patients worldwide.
Education and Training
Dr. Orfali earned her Medical Degree from the University of Baghdad and a Master of Business Administration in Pharmaceutical Science from Cambridge University. Her academic journey continued with a Fellowship in Pediatric Oncology/Hematology at Massachusetts General Hospital and Boston Children's Hospital. Furthermore, she has conducted clinical research in medical oncology at the prestigious Dana-Farber Cancer Research Institute.
About GEMMABio
GEMMABio is dedicated to transforming medical research into practical solutions that improve patient outcomes, particularly for those affected by rare diseases. The company's mission focuses on advancing gene therapy research, emphasizing the importance of ensuring global access to groundbreaking therapies.
Under the visionary leadership of Jim Wilson along with a team of experts in the field, GEMMABio aims to expedite the transition from laboratory discoveries to tangible therapies, making these innovations accessible and affordable.
Frequently Asked Questions
Who is Dr. May Orfali?
Dr. May Orfali is the newly appointed Chief Medical Officer of GEMMABio, bringing nearly 30 years of experience in clinical development.
What has Dr. Orfali accomplished in her career?
She has successfully held positions in various organizations, including Chief Medical Officer at Harbinger Health and Executive VP at Sigilon Therapeutics.
What is GEMMABio's mission?
GEMMABio aims to advance research and global access to innovative gene therapies for rare diseases.
Where did Dr. Orfali receive her education?
Dr. Orfali earned her Medical Degree from the University of Baghdad and her MBA from Cambridge University.
What impact will Dr. Orfali have at GEMMABio?
Her extensive experience in pharmaceuticals and clinical operations is expected to greatly benefit the company's growth and innovation.
